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for adjusted association with immunosuppressants in sub-
sequent regression models. Therefore, Dr. Mange can be
reassured that our results are not influenced by the mul-
tiple estimates of GFR per patient.
Second, Dr. Mange suggests that creatinine measure-
ments may be differentially missing between patients
who received different immunosuppressants. Nonran-
dom missing data could introduce bias if the annualized
change in GFR differed in patients with and without
missing creatinine measurements. All study patients had
three creatinine measurements recorded in the first two
post-transplant years, and over 80% of all creatinine mea-
surements were available during follow-up. There was no
association between missing creatinine values and trans-
plant year or type of immunosuppression; therefore, bias
caused by nonrandom missing values is very unlikely.
Third, Dr. Mange suggests bias caused by differences in
the methods used to measure creatinine between trans-
plant centers. In order for this to affect our results, the
creatinine assays in centers using tacrolimus (or my-
cophenolate) would have to systematically differ from
centers using cyclosporine (or azathioprine)—which
seems very improbable. Nonetheless, because most
patients would have creatinine measurements in the same
center, the annualized change in GFR in individual pa-
tients would not be affected by differences in assays be-
tween centers.
As discussed in our manuscript, we agree that readers
must consider a variety of limitations inherent to analy-
ses of large databases. However, we do not believe that
particular issues raised in this letter are relevant to our
analysis.
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Development of malignancy
after treatment of idiopathic
membranous nephropathy
To the Editor: With great interest, we have read
the paper in a recent issue of Kidney International by
Keiichi Yoshimoto et al [1] that pathologic findings
of initial biopsies reflect the outcomes of membranous
nephropathy (MN). In this study, seven patients (7/105 ×
100% = 6.66%) eventually died of malignancies (gastric
cancer 3, pancreatic cancer 1, lung cancer 1, laryngeal
cancer 1, leukemia 1). Although they were diagnosed
initially as idiopathic membranous nephropathy, we won-
dered whether the malignancy was the underlying cause
of MN or the complication of long-term immunosup-
pressive therapy (e.g., cyclophosphamide). MN had been
reported to be associated with neoplasms, and some
patients with malignancies had been documented pre-
senting with nephrotic-range proteinuria. In David’s
study [2], nine of 87 (9/87 × 100% = 10.3%) “idiopathic”
MN patients were associated with malignancy. Hence, a
search for malignancy is warranted in all adult patients
presenting with MN. Pathologically, deposits at sites other
than the subepithelial aspect of the glomerular basement
membrane (GBM) favor the presence of secondary forms
of MN. We would like to know if any deposits were
identified at mesangial, subendothelial, tubular basement
membrane, interstitial, or vessel area in these seven ma-
lignant patients. We would also like to know whether
there was any difference in the pathologic findings (ac-
cording to Yoshimoto’s classification) between the seven
malignant patients and those without malignancies. On
the other hand, the possible carcinogenic effect of long-
term immunosuppressive therapy should be also con-
sidered because the carcinogenic potency of alkylating
agents had been reported in the literature [3].
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Reply from the authors
We would like to thank you for the interest to our article
[1]. We agree with the comments that a search for malig-
nancy is warranted in all adult patients with membranous
nephropathy; therefore, we routinely examined them by
chest x-ray, upper gastrointestinal endoscopic study, ab-
dominal ultrasonography, or computed tomography, and
stool occult blood (if positive, lower gastrointestinal en-
doscopic study). Seven patients died with malignancy in
our study, but malignancy was not detected in all of them
at first as described [1].
Three of seven patients were treated with corticos-
teroid and cyclophosphamide, one patient with gamma
globulin and cyclophosphamide, two patients with corti-
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costeroids and cyclosporine A, and one patient with corti-
costeroids. We speculated that one patient with leukemia
at 11 months after cyclophosphamide treatment might
be related to the immunosuppressive therapy because
leukemia is well known as one of the early complica-
tions of cyclophosphamide therapy. It is also reported
that cyclosporine is related to malignant lymphoma, es-
pecially MALT lymphoma, but patients with cyclosporine
in our study didn’t develop lymphoma. In the cohort
study of Wegener’s granulomatosis treated by corticos-
teroids and cyclophosphamide in Sweden, Knight re-
ported that there was a 2-fold overall increased risk for
cancer. The increase was most pronounced for bladder
cancer (SIR = 4.8; 95% CI 2.6–8.1), squamous cell skin
cancer (SIR = 7.3; 95% CI 4.4–12), leukemia (SIR = 5.3;
95% CI 2.2–12) and for malignant lymphomas (SIR = 4.2;
95% CI 4.2–8.3) [2]. Hence, we should consider the risk
for cancer in the cases of long-term immunosuppressive
therapy.
Electron-dense deposits in glomerular lesions of ma-
lignancy showed various patterns (data not shown) as
in our previous report about hepatitis B virus–related
glomerulonephritis including hepatocellular carcinoma
[3]. In contrast, electron-dense deposits were identi-
fied only at subepithelial or intramembranous regions in
these seven patients. We judged these cases as idiopathic
membranous nephropathy in pathologic aspect. There
was statistically no significant difference in pathologic
findings at initial biopsies between the seven malignant
patients and those without malignancy. However, the
deep subgroup (two patients out of seven patients, 28.5%)
or heterogeneous type (4 patients out of 45 patients,
8.9%) tended to develop neoplasm during their clinical
course compared with those of homogeneous type with-
out deep subgroup (one patient out of 53 patients, 1.9%).
We need to further investigate the relation between the
electron-dense deposition pattern, especially deep sub-
group and malignancy.
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Plasma activin A in
hemodialysis patients: Does
brand of immunoassay matter?
To the Editor: Activin A is a newly recognized pluripo-
tent growth factor [1]. In a recent issue of Kidney Interna-
tional, we reported for the first time on plasma levels of
immunoreactive activin A in patients undergoing main-
tenance hemodialysis [2]. Predialysis levels were 143 ±
81.7 pg/mL in 25 patients, and not different from those
of 111 ± 67.1 pg/mL in 18 healthy subjects when mea-
sured with commercial colorimetric immunoenzymatic
assay kits from R&D Systems, Inc. (Quantikine; cat.
no. DAC00; Minneapolis, MN, USA). Presently, we de-
termined plasma activin A in another group of 35 chronic
hemodialysis patients using immunoenzymatic kits pur-
chased from Oxford Bio-Innovation, Ltd. (product code:
MCA1426KZZ; Oxfordshire, UK) [3]. Surprisingly, they
were a median of 978 (range 559 to 2560) pg/mL, and
more than 3-fold increased compared with those in 30
healthy control subjects (286 ± 127 pg/mL). The direct
comparison of the two immunoassays for activin A, yield-
ing such disparate results, was not possible because R&D
Systems had discontinued manufacturing the kit. At the
same time, serum activin A level measured recently
in healthy subjects by radioimmunoassay from Serotec
Limited (Oxford, UK) was about 400 pg/mL [4]. This re-
sult is closer to our present rather than our previous [2]
findings in healthy control subjects.
The issue whether predialysis plasma activin A level
in hemodialysis patients is actually normal or increased
remains thus unresolved. It deserves further studies em-
ploying standardized methods.
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